Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Mar 17:2023.03.13.23287208.
doi: 10.1101/2023.03.13.23287208.

Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials

Affiliations

Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials

Carlee B Moser et al. medRxiv. .

Update in

Abstract

Most clinical trials evaluating COVID-19 therapeutics include assessments of antiviral activity. In recently completed outpatient trials, changes in nasal SARS-CoV-2 RNA levels from baseline were commonly assessed using analysis of covariance (ANCOVA) or mixed models for repeated measures (MMRM) with single-imputation for results below assay lower limits of quantification (LLoQ). Analyzing changes in viral RNA levels with singly-imputed values can lead to biased estimates of treatment effects. In this paper, using an illustrative example from the ACTIV-2 trial, we highlight potential pitfalls of imputation when using ANCOVA or MMRM methods, and illustrate how these methods can be used when considering values <LLoQ as censored measurements. Best practices when analyzing quantitative viral RNA data should include details about the assay and its LLoQ, completeness summaries of viral RNA data, and outcomes among participants with baseline viral RNA ≥LLoQ, as well as those with viral RNA <LLoQ.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Distribution of SARS-CoV-2 RNA from nasopharyngeal swabs in Active and Placebo arms by study visit in overall cohort (A and B) and among those with vRNA ≥LLoQ at Baseline/Day 0 (C and D). Levels of SARS-CoV-2 RNA (log10 copies/ml) with horizontal line = median, box=interquartile range, whiskers = minimum/maximum (A and C); results below the LLoQ are plotted using an imputed value of 1 log10 copies/ml. Proportion with quantifiable SARS-CoV-2 RNA (green) and unquantifiable (purple) (B and D). LLOQ = Lower Limit of Quantification.
Figure 2:
Figure 2:
Quantile-quantile (Q-Q) plot for linear regression model for censored data for change in vRNA from baseline to Day 3 (A) and to Day 7 (B), both models included an indicator variable for treatment versus placebo and adjusted for baseline vRNA Standardized residuals (for the non-censored observations) calculated by dividing the residuals by their standard deviation (estimated from the fitted model). Quantiles for a standard normal distribution plotted on the x-axis take account of censored residuals.

References

    1. COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 2021; .
    1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. Massachusetts Medical Society; 2021; 385(23):e81. - PMC - PubMed
    1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. New England Journal of Medicine. Massachusetts Medical Society; 2021; 384(3):238–251. - PMC - PubMed
    1. Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021; :ciab912. - PMC - PubMed
    1. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. New England Journal of Medicine. Massachusetts Medical Society; 2021; 385(15):1382–1392. - PMC - PubMed

Publication types